Tadamasa Goto’s 2001 liver transplant at UCLA was both a medical intervention and the hidden hinge of an international arrangement: the FBI helped secure his entry to the United States in exchange for intelligence, while the transplant’s financing and the institutions’ knowledge of his criminal ties remained contested. The operation transformed a puzzling journey by a blacklisted crime figure into a story about law enforcement, scarce organs, and the limits of what investigators could establish.

Medical urgency and the journey to UCLA

In January or February 2001, doctors at Showa University told Goto that he would die without a liver transplant soon. He had hepatitis C and a heart condition, and was considered a very unlikely transplant candidate in Japan. In the summer of 2001, he received the transplant at the Dumont-UCLA Liver Cancer Center; the operation took place on July 5.

For months, Jake Adelstein had been investigating how Goto reached the United States. At first, he knew that Goto had undergone surgery at UCLA, had heard who the surgeon might be, and had conflicting estimates of the cost. He also knew that some hospital expenses had reportedly been sent from Japan through the Tokyo branch of a Las Vegas casino. Yet Goto was on the watch lists of U.S. Customs and Immigration, the FBI, and the DEA. His arrival appeared difficult to reconcile with his blacklisted status, and Adelstein suspected that the journey concealed a larger story.

The intelligence bargain

The explanation emerged in November 2006, when a Goto associate told Adelstein that the FBI had let Goto into the United States. Further reporting, drawing on sources in the U.S. Justice Department, Japanese police, and the underworld, reconstructed the arrangement. In April 2001, Goto approached the FBI through Hoshi Hitoshi, a former political fixer with deep connections to the Liberal Democratic Party.

The FBI wanted information about prominent yakuza because Japan’s National Police Agency had declined to share such information, citing privacy concerns. Goto offered a comprehensive list of Yamaguchi-gumi members, related front companies and financial institutions, as well as information about North Korean activities. In return, he wanted a U.S. visa so he could receive a transplant at UCLA. Goto arranged the UCLA treatment himself; the FBI’s role, as Adelstein reconstructed it, was to press U.S. Immigration and Customs to grant a visa, which the agency did reluctantly.

The bargain did not deliver what Goto had promised. After the operation, he returned to Japan and never spoke to the FBI again, having supplied only a fraction of the information. Adelstein’s account says there were no records of Goto returning to Japan. The transplant thus became inseparable from an intelligence exchange that opened the door to treatment but apparently yielded far less intelligence than the FBI had sought.

Payments and unanswered questions

The reported price varied sharply. Goto told an associate that he had paid $3 million for the liver; police reports put the figure at $1 million and speculated that his doctor had received $100,000 for each visit to Japan, usually at the Imperial Hotel. These were reported figures and allegations, not a settled accounting of the transplant’s costs.

The case also drew attention to the unequal pressures surrounding organ access. Japan had a stringent transplant system, with few donors and relatively rare operations; people needing organs often had to leave the country or die waiting. Against that scarcity, the treatment of Japanese patients with yakuza ties prompted questions about whether foreign patients with criminal records received access at the expense of law-abiding Americans. The evidence establishes the controversy, not that those patients were given priority over particular American candidates.

Adelstein also reported federal law-enforcement sources’ concern that payments to UCLA might have included proceeds from criminal activity in Japan. Such a transfer could constitute international money laundering, but the possibility was not established: to his knowledge, none of the four Japanese patients with yakuza ties treated at UCLA had been investigated for money laundering. Any such investigation would have required cooperation from Japanese authorities. Whether UCLA knew of the patients’ ties or the possible origins of payments remained unresolved.

Institutional findings and narrative consequence

It was never proven that UCLA or Dr. Busuttil knew, when the transplants were performed, that any of the patients had ties to the Japanese mafia. Both said that they treated patients according to medical need and did not make moral judgments about them; neither explicitly addressed what they knew about the four patients’ alleged ties. An investigation conducted by UCLA and the U.S. Centers for Medicare and Medicaid Services found no evidence of improper conduct, according to the Los Angeles Times. That finding did not settle the broader ethical questions about organ allocation, transparency, or the source of funds.

The transplant mattered to Adelstein’s reporting not simply because Goto had received treatment abroad, but because the apparent impossibility of his entry led toward the FBI deal. Goto was sufficiently concerned about disclosure that the investigation placed Adelstein in danger; his colleague Sekiguchi urged him to retreat without abandoning the story. The later account therefore holds together two kinds of uncertainty: a documented visa arrangement reconstructed from sources, and unresolved questions about what UCLA knew, how payments were made, and whether any money was illicit. The operation’s significance lies in that boundary between what the investigation could reveal and what it could not prove.